Highlights of PBTI Coimbra Conference on PRT of Plasma & Current Opinions on Pathogen Reduction Treatment of Blood Components

Transfusion and Apheresis Science

Volumn 52, Issue 2, 2015, Pages 228-232

  de Sousa, Gracinda ^a   Seghatchian, Jerard ^b  

^a Directive Board Portuguese Institute of Blood and Transplantation   (Portugal)

^b International Consultancy in Blood Components Quality Safety Improvement   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD COMPONENT; BLOOD SAFETY; COST EFFECTIVENESS ANALYSIS; DRUG SURVEILLANCE PROGRAM; ERYTHROCYTE; HUMAN; IN VITRO STUDY; LEUKOCYTE; PATHOGEN REDUCTION SYSTEM; PLASMA; PRODUCT SAFETY; PROGRAM EFFICACY; REVIEW; SCALE UP; STANDARD; THROMBOCYTE; TOTAL QUALITY MANAGEMENT; BLOOD COMPONENT THERAPY; COST BENEFIT ANALYSIS; ECONOMICS; PATIENT SAFETY; PORTUGAL; PROCEDURES; QUALITY CONTROL; STANDARDS; TREATMENT OUTCOME; TRENDS;

BLOOD COMPONENT TRANSFUSION; BLOOD PLATELETS; BLOOD SAFETY; COST-BENEFIT ANALYSIS; HUMANS; PATIENT SAFETY; PLASMA; PORTUGAL; QUALITY CONTROL; TREATMENT OUTCOME;

EID: 84930481789     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2015.02.010     Document Type: Review

References (17)

1. Pamphilon D. Viral inactivation of fresh frozen plasma. Br J Haematol 2000, 109:680-693.
2. Seghatchian J., Alain J.P. Current strategies for the provision of safer plasma and its derivatives; am update. Transfus Apher Sci 2001, 25:185-187.
3. Seghatchian J., de Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006, 35:189-196.
4. Bryant B.J., Klein H.G. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 2007, 131:719-733.
5. Solheim B.G., Seghatchian J. Chapter 51 Viral inactivation of blood components. Rossi AABB book 2009, 801-882. 4th ed.
6. Irsch J., Pinkoski I., Corash L., Lin L. Intercept plasma: comparability with conventional fresh frozen plasma based on coagulation function- an in vitro analysis. Vox Sang 2010, 98:47-55.
7. Hervig T., Seghatchian J., Apelseth T.O. Current debate on pathogen inactivation of platelet concentrates- to use or not to use?. Transfus Apher Sci 2010, 43:411-414.
8. Hellstern P., Solheim B. Transfus Med Hemother 2011, 38:65-70.
9. Marschner S., Goodrich R. Transfus Med Hemother 2011, 38:8-18.
10. Seghatchian J., Struff W., Reichenberg S. Transfus Med Hemother 2011, 38:55-64.
11. AuBouchon J.P. Update on the status of pathogen inactivation methods. Vox Sang 2011, 6:181-188.
12. Prowse C. Component pathogen inactivation: a critical review. Vox Sang 2012, 6:11-17.
13. FDA Blood Products Advisory Committee report 2012, Sep. 20.
14. Seghatchian J., Putter J.S. Pathogen inactivation of whole blood and red cell components: an overview of concept, design, developments, criteria of acceptability and storage lesion. Transfus Apher Sci 2013, 49:357-363.
15. Rock G. Theme article on SDP. Transfus Apher Sci 2014, 25:9-10.
16. Goubran H.A., Burnouf T., Stakiw J., Seghatchian J. Platelet microparticle: a sensitive physiological "fine tuning" balancing factor in health and diseases http://dx.doi.org/10.1016/j.transci.2014.12.015.
17. Salumkhe V., van de Meer P., Korte D., Seghatchian J., Gutierrez L. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands http://dx.doi.org/10.1016/j.transci.2014.12.016.